Gemelli Biotech Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$19M
- Investors
-
7
Gemelli Biotech General Information
Description
Developer of medical devices designed to provide diagnostics for the human microbiome. The company uses blood tests to measure the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome and also provides a breath test system that aids in the identification of small intestinal bacterial overgrowth, enabling physicians to get an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome.
Contact Information
Website
www.gemellibiotech.comCorporate Office
- 2020 Progress Court
- Suite 100-101
- Raleigh, NC 27608
- United States
Corporate Office
- 2020 Progress Court
- Suite 100-101
- Raleigh, NC 27608
- United States
Gemelli Biotech Timeline
Gemelli Biotech Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC (Series A) | 08-Jun-2022 | $19M | Completed | Generating Revenue | ||
3. Early Stage VC (Series A) | 07-Dec-2021 | Completed | Generating Revenue | |||
2. Seed Round | 27-Jun-2019 | $1.85M | $3.85M | Completed | Generating Revenue | |
1. Seed Round | 27-Nov-2018 | $2M | $2M | Completed | Startup |
Gemelli Biotech Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A1 | ||||||||
Series A2 | ||||||||
Seed Plus | 1,229,508 | $0.000100 | $2.44 | $2.44 | 1x | $2.44 | 6.73% | |
Seed | 1,333,332 | $0.000100 | $1.5 | $1.5 | 1x | $1.5 | 7.3% |
Gemelli Biotech Patents
Gemelli Biotech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021361055-A1 | Microbiome-derived gaseous sample collection system and methods | Pending | 16-Oct-2020 | ||
CA-3195531-A1 | Microbiome-derived gaseous sample collection system and methods | Pending | 16-Oct-2020 | ||
EP-4228797-A1 | Microbiome-derived gaseous sample collection system and methods | Pending | 16-Oct-2020 | ||
US-20220117513-A1 | Microbiome-derived gaseous sample collection system and methods | Pending | 16-Oct-2020 | ||
AU-2021361055-A9 | Microbiome-derived gaseous sample collection system and methods | Pending | 16-Oct-2020 | A61B10/0096 |
Gemelli Biotech Signals
Gemelli Biotech Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Carolina Angel Network | Angel Group | Minority | ||
Cedars-Sinai | Corporation | Minority | ||
CerraCap Ventures | Venture Capital | Minority | ||
LOUD Capital | Venture Capital | Minority | ||
New Day Venture Capital | Venture Capital | Minority |
Gemelli Biotech FAQs
-
When was Gemelli Biotech founded?
Gemelli Biotech was founded in 2018.
-
Where is Gemelli Biotech headquartered?
Gemelli Biotech is headquartered in Raleigh, NC.
-
What is the size of Gemelli Biotech?
Gemelli Biotech has 27 total employees.
-
What industry is Gemelli Biotech in?
Gemelli Biotech’s primary industry is Diagnostic Equipment.
-
Is Gemelli Biotech a private or public company?
Gemelli Biotech is a Private company.
-
What is Gemelli Biotech’s current revenue?
The current revenue for Gemelli Biotech is
. -
How much funding has Gemelli Biotech raised over time?
Gemelli Biotech has raised $57.7M.
-
Who are Gemelli Biotech’s investors?
Carolina Angel Network, Cedars-Sinai, CerraCap Ventures, LOUD Capital, and New Day Venture Capital are 5 of 7 investors who have invested in Gemelli Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »